Literature DB >> 10570277

A long-term memory obtained by genetic immunization results in full protection from a mammary adenocarcinoma expressing an EBV gene.

J Charo1, A M Ciupitu, A Le Chevalier De Préville, P Trivedi, G Klein, J Hinkula, R Kiessling.   

Abstract

We have tested the capability of a plasmid DNA (pDNA) expressing the EBV nuclear Ag-4 (EBNA-4) to evoke a T cell response-associated protective immune response against a tumor expressing this gene. We have found that ACA mice immunized with EBNA-4-expressing plasmid were partially protected against syngeneic mammary carcinoma line (S6C) expressing EBNA-4 (S6C-E4). This protection was enhanced by coimmunizing mice with EBNA-4- and GM-CSF-expressing plasmids, and a full protection was achieved by coimmunizing mice with EBNA-4- and IFN-gamma-expressing plasmids. Furthermore, mice that have rejected the EBNA-4-positive tumor were also resistant against a subsequent challenge with the original nontransfected tumor line. We then checked for the ability of pDNA immunization to provide a protective long-term memory response. We indeed found that even after 3 mo from the last immunization, full protection was obtained by this method, as compared with full tumor outgrowth in the control-immunized group. These findings support the concept that a nonviral, pDNA-based vaccination strategy is useful to fully protect from the outgrowth of tumors expressing this EBV gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570277

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Marked enhancement of the antigen-specific immune response by combining plasmid DNA-based immunization with a Schiff base-forming drug.

Authors:  Jehad Charo; Maria Sundbäck; Ken Wasserman; Anne-Marie T Ciupitu; Babak Mirzai; Ruurd van der Zee; Rolf Kiessling
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.

Authors:  Anna Kruschinski; Andreas Moosmann; Isabel Poschke; Håkan Norell; Markus Chmielewski; Barbara Seliger; Rolf Kiessling; Thomas Blankenstein; Hinrich Abken; Jehad Charo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-05       Impact factor: 11.205

3.  Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.

Authors:  Håkan Norell; Isabel Poschke; Jehad Charo; Wei Z Wei; Courtney Erskine; Marie P Piechocki; Keith L Knutson; Jonas Bergh; Elisabet Lidbrink; Rolf Kiessling
Journal:  J Transl Med       Date:  2010-06-07       Impact factor: 5.531

4.  Protective efficacy of a DNA influenza virus vaccine is markedly increased by the coadministration of a Schiff base-forming drug.

Authors:  Jehad Charo; Jan Alvar Lindencrona; Lena-Maria Carlson; Jorma Hinkula; Rolf Kiessling
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 5.  Vaccines and immunotherapeutics for the treatment of malignant disease.

Authors:  Joel F Aldrich; Devin B Lowe; Michael H Shearer; Richard E Winn; Cynthia A Jumper; Ronald C Kennedy
Journal:  Clin Dev Immunol       Date:  2010-09-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.